Literature DB >> 12444812

Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.

Sitra Tauscher-Wisniewski1, Shitij Kapur, Johannes Tauscher, Corey Jones, Zafiris J Daskalakis, George Papatheodorou, Irvin Epstein, Bruce K Christensen, Robert B Zipursky.   

Abstract

BACKGROUND: It has been suggested that transiently high dopamine-2 (D(2)) receptor occupancy by antipsychotic medication may be sufficient for inducing an antipsychotic response. We treated patients experiencing their first episode of schizophrenia with a single daily dose of quetiapine to achieve a transient daily peak of D(2) receptor blockade, to determine if this would lead to an antipsychotic response.
METHOD: Fourteen patients with a DSM-IV diagnosis of schizophrenia or schizophreniform or schizoaffective disorder were treated with quetiapine titrated to a single daily dose (mean +/- SD dose at the time of the positron emission tomography [PET] scan = 427 +/- 69 mg) for 12 weeks. Peak D(2) occupancy approximately 2 hours postdose and trough D(2) occupancy approximately 20 hours postdose were determined using PET and [(11)C]raclopride. Clinical symptoms and side effects were measured at baseline and every 2 weeks during the treatment phase.
RESULTS: Quetiapine administration led to a mean peak D(2) occupancy of 62% +/- 10% 2 hours postdose, which declined to 14% +/- 8% approximately 20 hours postdose. Ten (71%) of 14 patients responded to treatment with quetiapine, scoring "much improved" or greater on the Clinical Global Impressions-Improvement scale. Plasma drug levels and peak D(2) occupancy were highly correlated (r = 0.84; p =.003), as were prolactin and plasma drug levels when measured 2.5 hours after drug administration (r = 0.60; p <.05). Mean weight gain for the 10 subjects who completed the 12-week study was 4.2 +/- 4.6 kg (9.3 +/- 10.2 lb). No clinically relevant motor side effects occurred during the trial.
CONCLUSION: Patients with a first episode of schizophrenia responded to treatment with a single daily dose of quetiapine despite only transiently high D(2) receptor occupancy. Our findings raise the question of whether continuously high D(2) blockade is necessary for obtaining an antipsychotic response. Future studies aimed at evaluating the relative merits of "transiently high" versus "continuously high" D(2) occupancy are warranted.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12444812     DOI: 10.4088/jcp.v63n1106

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  21 in total

1.  Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia.

Authors:  Takefumi Suzuki; Hiroyuki Uchida; Hiroyoshi Takeuchi; Kensuke Nomura; Akira Tanabe; Koichiro Watanabe; Gohei Yagi; Haruo Kashima
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

2.  Treatment of first-episode non-affective psychosis: a randomized comparison of aripiprazole, quetiapine and ziprasidone over 1 year.

Authors:  Benedicto Crespo-Facorro; Victor Ortiz-Garcia de la Foz; Ignacio Mata; Rosa Ayesa-Arriola; Paula Suarez-Pinilla; Elsa M Valdizan; Obdulia Martinez-Garcia; Rocío Pérez-Iglesias
Journal:  Psychopharmacology (Berl)       Date:  2014-01       Impact factor: 4.530

3.  Serotonin2A receptor blockade and clinical effect in first-episode schizophrenia patients treated with quetiapine.

Authors:  Hans Rasmussen; Bjorn H Ebdrup; David Erritzoe; Bodil Aggernaes; Bob Oranje; Jan Kalbitzer; Lars H Pinborg; William F C Baaré; Claus Svarer; Henrik Lublin; Gitte M Knudsen; Birte Glenthoj
Journal:  Psychopharmacology (Berl)       Date:  2010-07-08       Impact factor: 4.530

Review 4.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications.

Authors:  Cenk Tek; Suat Kucukgoncu; Sinan Guloksuz; Scott W Woods; Vinod H Srihari; Aniyizhai Annamalai
Journal:  Early Interv Psychiatry       Date:  2015-05-12       Impact factor: 2.732

6.  Effects of Community Mental Health Service in Subjects with Early Psychosis: One-Year Prospective Follow Up.

Authors:  Eun-Jin Na; Nam-In Kang; Mi-Young Kim; Yin Cui; Hee-Eon Choi; Ae-Ja Jung; Young-Chul Chung
Journal:  Community Ment Health J       Date:  2015-11-28

7.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 8.  Quetiapine: dose-response relationship in schizophrenia.

Authors:  Anna Sparshatt; Sarah Jones; David Taylor
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 9.  [Atypical antipsychotics and metabolic syndrome].

Authors:  Andreas Baranyi; Renè Yazdani; Alexandra Haas-Krammer; Alexandra Stepan; Hans-Peter Kapfhammer; Hans-Bernd Rothenhäusler
Journal:  Wien Med Wochenschr       Date:  2007

10.  New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine.

Authors:  Bernhard T Baune
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.